XTRA:BAYNPharmaceuticals
Will Bayer's VVD-214 Oncology Bet and J.P. Morgan Update Change Bayer's (XTRA:BAYN) Narrative
Vividion Therapeutics, Bayer’s wholly owned subsidiary, recently published on the cover of the Journal of Medicinal Chemistry its discovery and optimization of VVD-214, a covalent Werner helicase inhibitor now in Phase I trials for MSI-high cancers, including in combination with pembrolizumab.
This work showcases Bayer’s use of chemoproteomics and a covalent-first approach to pursue targeted oncology therapies that may diversify and deepen its pharmaceutical pipeline.
We’ll now examine how...